Clinical Benefits
Relieves neuromuscular pain: Magnesium exerts muscle-relaxing actions (and prevents muscle spasms) via multiple mechanisms and is a natural glutamate antagonist.1 Glutamate is involved in central sensitisation and pain amplification.2 Magnesium regulates neuromuscular transmission by blocking the entry of calcium ions in synaptic nerve terminals,3 as well as inhibiting presynaptic acetylcholine release, which propagates impulses between motor nerves and muscles.4
Higher magnesium intake has found to be protective against chronic pain.5 However, one third of Australian adults fail to meet their requirements for adequate magnesium intake.6 PainX contains 420 mg/d to support adults to meet the recommended intake of 310 to 320 mg/d in women and 400 to 420 mg/d in men.7
Palmitoylethanolamide (PEA) promotes endogenous cannabinoid system (ECS) activity through its ability to augment the activity of cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).8 These receptors are expressed in nerve tissue and immune cells and are involved in modulating the inflammatory response by suppressing immune cell activation, which can reduce pain perception.9 PEA proves to be effective and safe in nerve compression syndromes. In one pivotal, double blind, placebo-controlled trial in 636 sciatic pain patients, subjective pain scores were reduced from 6.5/10 to 3.6/10 in the 300 mg/d group, while in the 600 mg/d group scores were reduced from 7.1/10 to 2.1/10 compared to placebo, which decreased from 6.6/10 to 4.6 (Figure 2).10
Meta Mag® and Levagen+™ are both exclusive types of magnesium and PEA, respectively, that show enhanced bioavailability.11 Meta Mag® is different to magnesium salts and other magnesium chelates because it is covalently bound to two glycine molecules.12 Levagen+™ is a highly bioavailable PEA using LipiSperse® technology for enhanced absorption.13 The Levagen+™ absorption studies show that Levagen+™ is 1.7 times better absorbed and that it stays in the plasma for a longer period of time compared to a standard PEA (Levagen®) (Figure 3). Clinically, 600 mg/d of Levagen+™ PEA is likely to equate to consuming 1,000 mg/d of a standard micronised PEA (Levagen®). A Practitioner can expect Levagen+™ to produce greater efficacy and to last longer in the body.14
PainX contains 750 mg of malic acid per dose.
Levagen+™ is owned by Gencor Pacific Limited. Meta Mag® is a registered trademark of Balchem Corp.
